Case study · agentic diagnostic system
liteOdyssey
Rare-disease diagnosis with a reasoning process you can inspect.
How it works
- 01 / InputPatient phenotype
HPO-coded features, with or without genetic findings.
- 02 / InvestigationPolicy + biomedical tools
A reasoning model gathers and checks evidence under a written diagnostic policy.
- 03 / OutputRanked differential
Diseases and genes, with the evidence and tool calls behind each rank.
The learning happens in the policy. Expert review gates revisions; model weights stay fixed.
Explore the diagnostic workflow and policy-development loop
Diagnose one case
The policy decides which evidence to gather and when.
Diagnostic policyThe policy is a natural-language document that integrates expert diagnostic reasoning principles, specialized biomedical tools and the rules for using them, organized as an eight-phase workflow. Development updates the policy; model weights stay fixed.natural language · workflow, tools and the rules for using them
ToolsThe tools are part of the policy, and each phase specifies which ones it draws on. When a failure traced to the evidence a tool returned, its specification was revised, so the workflow, phase criteria and tools co-evolved.
Main path
dx-monarchphenotype to gene candidates
dx-omimdisease and family review
Called when the answer could change the ranking
dx-clingencurated calibration
dx-gene-evidenceconstraint tiebreak
dx-pubmedtargeted literature
How the policy learned
Policy Iteration with Human Feedback
- Run the current policy on the 50-case development set
- Locate recurrent failures by reasoning stage
- Gate revisions clinically
- Persist the improved policy
↺ next evaluation round
Model weights stay frozen. The written policy transfers across models.
The harness that automates this loop: PIHF-MCP
Performance
Disease Recall@1, matched baseline vs LiteOdyssey (GPT-5.4)
1,193 of the public cases, covering 679 diseases, were never used in policy development. Four reasoning models each improved over their matched baselines (baselines 18.7% to 26.5%). In the UDN cohort, blinded physician review corroborated the gain.
Matched baseline: the same model and clinical features without the policy or tools. Public-benchmark scores use a judge from a different model family than the one evaluated; exact-OMIM sensitivity analyses are in the preprint.
Notes
Contribution. I designed and implemented LiteOdyssey and am first author of its preprint.
Go deeper. liteodyssey.org has the method, the full evidence and a reviewer workspace. The preprint: arXiv 2606.16149.